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agreed that patients with the syndrome who have experienced 
syncopal episodes or been resuscitated from cardiac arrest 
should receive an implantable cardioverter defibrillator 
(ICD).[3] However, controversies exist in the treatment of 
asymptomatic patients who might become symptomatic and 
develop sudden cardiac death resulting from the ﬁ  rst attack 
of ventricular ﬁ  brillation (VF).
Long-QT syndrome (LQTS) is a cardiovascular disorder 
characterized by prolongation of the QT interval on the 
surface ECG and episodes of syncope and/or life-threatening 
cardiac arrhythmias, speciﬁ  cally of polymorphic ventricular 
tachycardia (VT) (torsade de pointes [TdP]). The molecular 
basis of LQTS is the prolongation of action potential 
duration resulting from defects in several ion channel genes. 
Mutations in KCNQ1 (LQT1) and HERG (LQT2) cause 
INTRODUCTION
Brugada syndrome and congenital long-QT syndrome type 
3 (LQT3) are 2 allelic diseases associated with mutations in 
SCN5A gene that encodes the cardiac sodium channel α 
subunit. Brugada syndrome was ﬁ  rst described as a clinical 
entity by Brugada and Brugada in 1992.[1] It is characterized 
by a typical electrocardiogram (ECG) pattern of ST-segment 
elevation in leads V1 through V3, a complete or incomplete 
right bundle-branch block (RBBB), and a high incidence of 
sudden cardiac death in patients with structurally normal 
hearts. The syndrome is believed to be responsible for at 
least 4% of all sudden deaths and at least 20% of sudden 
deaths in patients with structurally normal hearts.[2] It is 
inherited in an autosomal dominant mode and SCN5A gene 
is an important gene to be linked to the disease. It has been 
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ABSTRACT
Background: Brugada syndrome and congenital long-QT syndrome (LQTS) type 3 (LQT3) are 2 inherited 
conditions of abnormal cardiac excitability characterized clinically by an increased risk of ventricular 
tachyarrhythmias. SCN5A gene that encodes the cardiac sodium channel α subunit is responsible for the 2 
diseases, and more work is needed to improve correlations between SCN5A genotypes and associated clinical 
syndromes. Methods and Results: Four patients diagnosed as having Brugada syndrome, 9 patients suspected 
to have Brugada syndrome, and 3 LQTS patients suspected to be LQT3 without mutations in KCNQ1 and 
HERG participated in the study. DNA samples from these patients were analyzed using direct sequencing. 
One patient with Brugada syndrome had 2 novel mutations, V95I and A1649V. The former was identiﬁ  ed in 
the N-terminus of SCN5A and the latter was in the DIVS4/S5 linker of SCN5A. One patient suspected to have 
Brugada syndrome had a mutation, delF1617, in the DIIIS3/S4 linker of SCN5A. A novel mutation in the 
C-terminus of SCN5A, delD1790, was found in a patient with LQT3. No other mutations of SCN5A were found 
in the remaining patients. These 4 mutations were not detected in 50 unrelated control subjects. Conclusions: 
Two novel and a reported SCN5A mutations were found in Chinese patients with Brugada syndrome, and a 
novel SCN5A mutation was found in a Chinese patient with LQT3.
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defects in the delayed rectiﬁ  er potassium currents,[4,5] whereas 
mutations in SCN5A (LQT3) cause a persistent cardiac 
sodium current.[6] LQT1 and LQT2 account for ≈90% of 
all genotyped patients. LQT3 is about 10–15% of all LQTS.
[7] LQT3 has different features from LQT1 and LQT2. One 
of the most important clinical features is the basic therapy for 
LQTS, β-blocker, is less effective for LQT3, but mexiletine 
and ﬂ  ecainide might be beneﬁ  cial.[8] 
Determination of Brugada syndrome or LQT3-associated 
mutations can improve presymptomatic diagnosis, enable 
better follow-up of asymptomatic patients and facilitate 
choosing effective therapies earlier. In this study, we 
performed a genetic analysis in the translated region of 
SCN5A in the following Chinese patients: 4 patients 
diagnosed as Brugada syndrome, 9 patients suspected to 
have Brugada syndrome, and 3 LQTS patients suspected 
to be LQT3 without mutations in KCNQ1 and HERG. 
We identiﬁ  ed 2 novel and a reported SCN5A mutations 
in patients with Brugada syndrome and a novel SCN5A 
mutation in a patient with LQT3. 
SUBJECTS AND METHODS
Subjects
Four unrelated sporadic patients diagnosed as having Brugada 
syndrome, 9 unrelated sporadic patients suspected to have 
Brugada syndrome, and 3 unrelated patients suspected to be 
LQT3 without mutations in KCNQ1 and HERG conﬁ  rmed 
by a previous research.[9] The patients and control subjects 
who participated in this study were all Chinese, all of whom 
provided informed consent, and were recruited from the 
Department of Cardiology, Peking University People’s 
Hospital, China. Clinical diagnosis of Brugada syndrome was 
based on a consensus report in 2005,[3] namely, a typical ECG 
pattern characterized by a coved ST-segment elevation   ≥   2 
mm in more than 1 right precordial lead (V1 to V3) at baseline 
in association with 1 or more clinical ﬁ  ndings that include 
syncope, documented VF/polymorphic VT, or a family 
history of sudden cardiac death at age less than 45 years, and 
no other explanation for the ECG abnormality. The patients 
suspected to have Brugada syndrome were those having 
syncope, normal echocardiograms, and a coved ST-segment 
elevation < 1 mm (1 patient) or a saddleback ST-segment 
elevation (7 patient) or a normal ECG (1 patient). LQT3 was 
suspected on the basis of QTc (the QT interval corrected 
for heart rate) ≥ 460 ms and late onset of abnormal T wave, 
the presence of syncope or TdP, and excluding acquired 
LQTs.[10] Clinical and laboratory investigations included a 
review of medical history, a complete physical examination, 
12-lead ECG, 24-h ambulatory electrocardiographic 
monitoring (Holter), transthoracic echocardiography, and 
blood biochemical test. 
The control samples consisted of 50 unrelated healthy 
Chinese. None had Brugada-type or QT interval prolongation 
ECG ﬁ  ndings, or a history of VT/VF or syncope. The 
protocol was approved by the Health Sciences Research 
Ethics Board of the Peking University.
Mutation analysis
Genomic DNA was prepared from the peripheral blood 
lymphocytes by standard methods. All 28 exons of the 
SCN5A gene were ampliﬁ  ed by polymerase chain reaction 
(PCR) using primers designed by Wang et al.[11] The PCR 
products were ampliﬁ  ed and sequenced on both strands 
by the dideoxynucleotide chain termination method with 
ﬂ  uorescent dideoxynucleotides, using an ABI 377 automated 
sequencer. The obtained sequence data were compared with 
previously reported SCN5A cDNA sequence (GenBank 
Accession number GI: 37622906). The probands were 
analyzed for mutations ﬁ  rst. If a proband was found to 
have a mutation, the patient’s family members and control 
subjects would be investigated for the mutation in the exon 
where mutation occurs. 
RESULTS
Patients diagnosed with Brugada syndrome
Four patients diagnosed with Brugada syndrome were all 
men presenting syncope. Each patient had a coved-type ST-
segment elevation ≥ 2 mm in leads V1 to V2 on the 12-lead 
ECG. RBBB was noted in 3 patients (patient 1, 2, and 4). A 
family history of sudden cardiac death at <45 years of age was 
noted in 1 patient (patient 2). All patients were recommended 
ICD, but none could afford the therapy. During follow-up, 
patient 2 was lost; patients 1, 3, and 4 were followed-up for 
60, 7, and 24 months, respectively. No syncope occurred in 
3 patients except that patient 4 had presyncope occasionally. 
Patient 1, 38 years old, had ﬁ  rst syncope at the age of 33 
years at rest in the night. He had a typical ECG of Brugada 
syndrome [Figure 1] and no abnormal physical condition and 
other signiﬁ  cant laboratory abnormalities.
The 4 patients with clinical evidence of Brugada syndrome 
were sequenced for mutations in SCN5A. Two novel 
mutations were identiﬁ  ed in patient 1. One heterozygous 
missense mutation was a G→A transition at nucleotide 
position 283 in exon 3 of SCN5A [Figure 2, upper panel] 
that led to the replacement of Valine by Isoleucine at codon 
95 (V95I) in the N-terminus of the human cardiac sodium 
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Figure 1: Twelve-lead electrocardiogram record of patient 1 with 
Brugada syndrome showing the ST-segment elevation in leads V1 to 
V2 and the  incomplete right bundle-branch block pattern
Figure 2: Direct sequence analyses of PCR-ampliﬁ  ed DNAs of SCN5A 
in patient 1 with Brugada syndrome. (a) There was a G to A substitution 
of codon 95 (Upper), (b) and a C to T substitution of condon 1649 
(Lower), respectively.
Figure 3: Predicted topology of the cardiac Na+ channel is illusturated 
with locations of mutations associated with either BrS or LQT3found 
in the present study
Figure 4: Detection of mutation in the family members. (a) Partial 
family members of patient 1 with Brugada syndrome. (b) Partial family 
members of patient 9 suspected to have Brugada syndrome. (c) Partial 
family members of patient 3 with LQT3. (Circles) Females; (Squares) 
males; empty symbols depict unaffected members; ﬁ  lled symbols depict 
mutation carriers with symptoms; half-ﬁ  lled symbols depict mutation 
carriers without symptoms; the proband is indicated by an arrow
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channel α subunit [Figure 3]. The other heterozygous 
missense mutation was a C→T transition at nucleotide 
position 4946 in exon 28 of SCN5A [Figure 2b], which was 
predicted to result in substitution of Alanine with Valine 
at codon 1649 (A1649V) in the S4/S5 linker in domain 
IV of SCN5A [Figure 3]. The parents of patient 1 were 
investigated [Figure 4a] and the other relatives of patient 1 
refused to undergo mutation analyses. The father (II-1) was 
a heterozygous carrier of V95I and A1649V mutations. But 
he was asymptomatic with normal ECG. The mother (II-2) 
did not have the mutation. 
Patients suspected to have Brugada syndrome
Nine patients suspected to have Brugada syndrome were all 
men who refused to take dru g challenge with sodium channel 
blockers. A family history of sudden cardiac death at <45 
years of age was noted in only 1 patient (patient 4). None 
had physical and other signiﬁ  cant laboratory abnormalities. 
Patient 9, 16 years old, was a student who had ﬁ  rst syncope 
at rest in the last year. No syncope occurred thereafter but 
he often had palpitations at rest. He had normal ECG and 
didn’t receive any treatment. 
One mutation was found in patient 9. The heterozygous 
deletion mutation was 3 nucleotides (TCT) deletion at 
nucleotide position 4850–5852 in exon 28 of SCN5A 
[Figure 5] that caused Phenylalanine deletion at codon 1617 
(delF1617) in the S3/S4 linker in domain IV of the human 
cardiac sodium channel [Figure 3]. The parents of patient 9 
were investigated [Figure 4b] and the other relatives refused 
mutation analyses. The father (II-1) was a heterozygous carrier 
of the delF1617 mutation. But he was asymptomatic with 
normal ECG. The mother (II-2) did not have the mutation.
Patients diagnosed with LQT3
Three patients diagnosed with LQT3 were all female with 
syncope or presyncope occurring at rest. All patients had 
QTc prolongation (519, 639, and 562 ms, respectively) and 
a
bJ Cardiovasc. Dis. Res. Vol. 1 / No 2 72 Available Online: www.jcdronline.org
Figure 5: Sequence analyses of patient 9 suspected to have Brugada 
syndrome showed a three nucleotides (TCT) deletion at position 4850-
5852 at codon 1617
Figure 6: The twelve-lead ECG of patient 3 with LQT3 showed that QTc 
562ms and delayed T-wave onset with biphasic T-wave morphology
Figure 7: Sequence analyses of PCR products of exon 28 in SCN5A 
in patient 3 with LQT3. A three nucleotides (GAC) deletion at position 
5368-5370 at codon 1790 was identiﬁ  ed
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late-onset abnormal T wave on the 12-lead ECG. None 
had physical and other signiﬁ  cant laboratory abnormalities. 
Patient 1 was implanted a pacemaker because of complete 
atrioventricular block (III°AVB) and syncope did not occur 
in the following one and a half years. Patient 2 accepted left 
cardiac sympathetic denervation and syncope did not occur 
in the following 3 years. Patient 3, 27 years old, had recurrent 
presyncope for 4 years. Taking β-adrenergic blockers within 
therapeutic doses, she became sleepy and discontinued 
the medicine. She refused any other treatment including 
mexiletine. Her ECG was shown in Figure 6. 
A novel mutation was found in patient 3. The heterozygous 
mutation was 3 nucleotides (GAC) deletion at nucleotide 
position 5368–5370 in exon 28 of SCN5A [Figure 7] that 
caused Aspartic acid deletion at codon 1790 (delD1790) in 
the C-terminus of the human cardiac sodium channel [Figure 
3]. The parents of patient 3 were investigated [Figure 4c] and 
the other relatives refused mutation analyses. Her mother 
(II-2) was a heterozygous carrier of the delD1790 mutation. 
She also had a typical LQT3 ECG and syncope episodes. 
Her father (II-1) did not have the mutation. 
Analysis of 100 control chromosomes did not identify the 4 
mutations (V95I, A1649V, delF1617, and delD1790).
DISCUSSION
In the present study, the genetic nucleotide sequence of 
SCN5A was analyzed in both the Chinese patients with 
Brugada syndrome and Chinese patients with LQT3 and 
control subjects. We identified 2 novel single missense 
mutations, V95I and A1649V, which to our knowledge have 
not been previously reported in unrelated Chinese Brugada 
patients, and a reported deletion mutation, delF1617, in a 
patient suspected to have Brugada syndrome, and a novel 
deletion mutation, delD1790, which to our knowledge has 
not been previously reported in Chinese LQT3 patients. 
SCN5A mutations can cause Brugada syndrome and 
LQT3. The reason that SCN5A mutations cause different 
phenotypes might be the complex relationships between 
structure and function of the SCN5A protein. Different 
mutations cause different diseases and also different gating 
or conductance changes of the sodium channel. SCN5A Available Online: www.jcdronline.org 73 J Cardiovasc. Dis. Res. Vol. 1 / No 2
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mutations associated with Brugada syndrome render loss 
of function of the sodium channel because of the changes 
in the gating function of the sodium channel, including 
accelerated inactivation, slow reactivation, and entry of the 
sodium channel into an intermediate state of inactivation[12-14]; 
a decrease in the number of the sodium channel in the 
membrane resulting from failure of the sodium channel 
to express or intracellular trafﬁ  cking defects;[15] destroyed 
conductance function of the sodium channel owing to 
mutations in the pore region of the channel.[16] The reduction 
in Na+ current, especially in the epicardial cells will generate 
a potential gradient that can manifest as ST-segment elevation 
on the ECG. Different from Brugada syndrome, LQT3 is 
associated with SCN5A mutations that result in slowing or 
an increase in the reversibility of inactivation and an increase 
in the late component of sodium current.[17-20] The increase 
in late current prolongs the action potential duration and the 
QT interval on the ECG. 
The SCN5A channel is a transmembrane protein composed 
of 4 homologous domains (DI–DIV), each containing 6 
transmembrane segments (S1–S6). In the present study, V95I 
and A1649V mutations were found in a patient diagnosed 
with Brugada syndrome. V95I was in the N-terminus of 
the SCN5A channel. Priori et al. and Levy-Nissemna et al. 
reported that R27H, G35S, and R104Q mutations with 
Brugada syndrome were in the N-terminus of the SCN5A 
channel.[21,22] But there were no electrophysiologic data about 
these mutations. A1649V was found in the S4/S5 linker in 
domain IV of SCN5A. To our knowledge, no mutations 
linked to Brugada syndrome in the S4/S5 linker in domain 
IV were reported previously. The role of N-terminus and S4/
S5 linker in domain IV in gating and conductance function 
of the Na+ channel was not clear. We searched the SCN5A 
homology in several different isoforms (SCN4A, SCN1A, 
SCN3A, SCN8A, SCN9A) for sequence changes in the V95 
and A1649, but no sequence variant was found at codon 
95 and 1649, suggesting that the 2 positions are conserved. 
A1649 was the second amino acid residue next to DIVS4, 
which has been proved to be a voltage sensor responding to 
the changes in membrane potential and plays an important 
role in activation, fast inactivation, and slow inactivation of 
the sodium channel. Therefore, V95 and A1649 might have 
effects on maintaining the normal function of the sodium 
channel and A1649 might be associated with gating function 
of the sodium channel. In our study, the proband with V95I 
and A1649V had syncope and a typical Brugada syndrome 
ECG and the 2 amino acid changes were not found in 
100 control chromosomes. Thus, the V95I and A1649V 
changes are likely to be mutations and not polymorphisms. 
The pattern in which the 2 mutations occurred in the family 
conformed to the autosomal dominant inheritance mode. The 
reason that the proband’s father had the same mutations as the 
proband but had normal ECG and no symptoms might be 
incomplete penetrance of Brugada syndrome and inﬂ  uences 
of environmental factors, such as temperature and genetic 
factors, such as regulatory genes. 
DelF1617 mutation found in a patient suspected to have 
Brugada syndrome in our study was in the extracellular linker 
between segments S3 and S4 in domain IV of SCN5A. The 
mutation was originally reported and tentatively associated 
with LQT3 by Splawski et al. in 2000[23] In 2005, Chen et al.[24] 
assessed the biophysical properties of the mutant channel. 
Compared with the wild type, the inactivation of delF1617 
was faster and the mean channel open times were shorter 
at negative potentials, whereas it tended to be the opposite 
at positive potentials. The authors concluded that this 
mutation can cause either a gain or loss of sodium current 
depending on the membrane potential. The results of in 
vitro expression displayed a potential for this mutation to 
induce an overlapping BrS-LQT3 phenotype. But no clinical 
data are currently available to support this hypothesis. In 
the present study, the proband and his father who carried 
delF1617 mutation had normal ECG. They refused to take 
drug challenge with sodium channel blockers. As the ECG 
patterns of Brugada syndrome can be dynamic and often 
concealed, and the biophysical properties of delF1617 mutant 
channel, the proband is most likely to be diagnosed with 
Brugada syndrome. 
Numerous mutation analyses of LQT3 have shown that 
C-terminus appears to be a “hot-spot” for LQT3 mutations. 
Homology modeling of the SCN5A C-terminus predicts that 
the ﬁ  rst half of the C-terminus domain consists of 6 helices 
(H1–H6), which are highly conserved among different human 
sodium channel isoforms, particularly the acid rich domain, 
containing H1 and H2.[25] Functional studies revealed that 
the proximal half of the C-terminus containing all of the 
helical structure markedly modulates channel inactivation 
but not activation. Studies of inherited mutations in the 
ﬁ  rst 5 helices of the proximal region of the C-terminus, 
such as E1784K, D1795insD, Y1795C, and D1790G have 
indicated that all these mutations cause changes in channel 
inactivation with no reported effects on channel activation.
[26-29] Moreover, E1784K mutation imposes allosteric rather 
than a direct effect on channel gating, whereas D1790G 
mutation induces changes in the interaction between the Na+ 
channel α-    and  β1-subunits. H1 is composed of 14 amino 
acid residues, among which only 3 are hydrophobic and the 
others are all hydrophilic. Asp1790, the third amino acid 
residue in H1, is hydrophilic and conserved among different 
human sodium channel isoforms (SCN5A, SCN2A, SCN8A, 
SCN9A, SCN4A). Deletion of Asp1790 will alter the primary J Cardiovasc. Dis. Res. Vol. 1 / No 2 74 Available Online: www.jcdronline.org
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structure of SCN5A protein that is closely associated with the 
overall structure and function of the protein. Therefore, we 
speculate that DelD1790 might inﬂ  uence the stability of H1 
α-helical structure by changing the primary structure of the 
protein which in turn interrupts inactivation of Na+ channel. 
However, the fact that DelD1790 mutation inﬂ  uences the 
interaction between the Na+ channel α- and β1-subunits 
cannot be overlooked.
The failure to identify mutations in some individuals in our 
study may result from genetic heterogeneity, presence of 
mutations in regulatory sequences, or phenotypic errors. In 
a future study, we shall conduct functional analyses of the 
mutations using a mammalian expression system, which may 
help clarify the pathogenic involvement of these mutations. 
We shall also attempt to identify additional genes that may be 
responsible for the Brugada syndrome or LQT3.
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